Review says spontaneous sarcoid regression in horses is rare: full analysis
Version 2 — Full analysis
A new Equine Veterinary Journal review is reframing a familiar point of debate in equine oncology: spontaneous regression of sarcoids does happen, but Sabine Brandt argues it should be considered exceptional rather than expected. That distinction matters because equine sarcoids are the most common skin tumors in horses, they’re often persistent and recurrent, and clinical decisions can be distorted if rare self-resolution is mistaken for a common natural course. (pubmed.ncbi.nlm.nih.gov)
The background is messy, which is exactly why the review matters. Sarcoids are benign, non-metastatic tumors, but they’re locally aggressive and clinically diverse, ranging from occult and verrucous lesions to fibroblastic, mixed, and malevolent forms. They’re closely associated with bovine papillomavirus, especially BPV-1 and BPV-2, and likely BPV-13 in some cases. Over time, the field has had to reconcile two competing observations: naturally occurring sarcoids are often stubborn and recurrent, yet some experimental or mild naturally occurring lesions have regressed, raising questions about host immunity and whether a subset of cases can clear disease without intervention. (pmc.ncbi.nlm.nih.gov)
That tension shows up clearly in the published literature. A 2016 longitudinal study of 61 young Franches-Montagnes horses found that 29 of 38 horses affected at age three became lesion-free without therapy at follow-up, with regression concentrated in milder occult and verrucous lesions. The authors said those findings could justify a monitored wait-and-see approach in selected mild cases. But more recent treatment data point the other way in many settings: one prospective topical-treatment study reported spontaneous remission in just 1.9% of untreated tumors, and a 2024 systematic review concluded that the sarcoid treatment evidence base remains highly heterogeneous and at very low quality overall. That review also warned that spontaneous regression can complicate interpretation of uncontrolled studies, making it harder to know whether a therapy truly worked. (pubmed.ncbi.nlm.nih.gov)
Brandt’s review appears to land in that gap by emphasizing that regression is real, but uncommon enough that clinicians shouldn’t build routine management around it. The biologic rationale is plausible. Sarcoids are papillomavirus-associated tumors, and both experimental infection studies and newer immunotherapy work suggest immune responses can influence lesion behavior. In one 2021 study, an influenza-virus-vectored immunotherapy induced regression of both injected and non-injected sarcoids, supporting the idea that systemic antitumor immunity can be triggered under the right conditions. That doesn’t mean untreated field cases will behave the same way, but it does reinforce the review’s focus on immunologic factors as a key part of the story. (pubmed.ncbi.nlm.nih.gov)
Industry and expert commentary around sarcoids has long reflected the same caution. Reviews and educational resources consistently describe sarcoids as common, frustrating lesions that can worsen after accidental or iatrogenic trauma and can carry substantial welfare and economic consequences. A recent review of papillomavirus-like particles in equine medicine noted that sarcoids may affect up to 12% of horses worldwide, can compromise use, and in severe cases contribute to euthanasia decisions. Meanwhile, the 2024 systematic review stopped short of recommending one treatment strategy over another because of weak comparative evidence, though it suggested radiotherapy and multimodal approaches may deserve consideration where available. (pmc.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the practical takeaway is less about whether spontaneous regression exists and more about how much weight to give it. If Brandt’s framing gains traction, it could push clinicians to reserve observation for carefully selected mild lesions, while being more proactive with lesions in high-friction areas, cosmetically sensitive sites, or cases at risk for progression after manipulation. It also sharpens conversations with pet parents: “benign” doesn’t mean inconsequential, and “sometimes regresses” doesn’t mean likely to regress. From a research standpoint, the review also underscores a methodological problem. When spontaneous regression is inconsistently defined, and untreated controls are scarce, treatment claims become harder to trust. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next step to watch is whether future sarcoid studies use better-controlled designs, stratify lesions by type and location, and incorporate immunologic endpoints that can help explain why a small minority regress while most persist. There’s also a broader translational angle: ongoing work in papillomavirus-targeted immunotherapy, viral biology, and host response could eventually turn a rare natural event into a more predictable therapeutic one. (pubmed.ncbi.nlm.nih.gov)